Efficacy of Aprepitant in Treatment of Chemotherapy-induced Nausea and Vomiting in Patients with Advance Breast Cancer

JIANG Min; CHI Feng; ZENG Yue-can

doi:10.3969/j.issn.1002-3429.2017.03.035

Abstract：Objective To observe efficacy and safety of Aprepitant in treatment of chemotherapy-induced nausea and vomiting in advanced breast cancer patients treated with Cisplatin.Methods A total of 56 advanced breast cancer patients treated with Cisplatin during January 2014 and May 2016 were divided into observation group (n=28) and control group (n=28) according to random digits table method.Observation group was treated with 125 mg/d Aprepitant one hour before medication on the first day of chemotherapy,and 80 mg/d Aprepitant was taken orally in the morning on the 2nd and 3rd days,and 5 mg/d Granisetron and 5 mg/d Dexamethasone were given by intravenous push at the same time.Control group was treated with placebo,Granisetron and Dexamethasone with the same dosage and method.Results There were no significant differences in incidence rates of acute nausea,delayed nausea,acute vomiting,delayed vomiting and acute nausea and vomiting in the two groups (P>0.05).Compared with those in control group,incidence rate of delayed nausea and vomiting was significantly decreased in observation group (P=0.043).There were 17 patients without nausea or vomiting in observation group and 9 patients without nausea or vomiting in control group,and the difference was statistically significant (P<0.05).There were no significant differences in other incidence rates of adverse reaction between the two groups (P>0.05),and no moderate or severe adverse reaction was found by Aprepitant.Conclusion Aprepitant in treatment of chemotherapy-induced nausea and vomiting in advanced breast cancer patients treated with Cisplatin can achieve good effect and safety.